Climate Change Data

Genmab A/S

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:147,721 tCO2e (2022)
Scope 1 Emissions:317 tCO2e (2023)
Scope 2 Emissions:238 tCO2e (2023)
Scope 3 Emissions:147,327 tCO2e (2022)
Renewable Energy Share:76.8% (2023)
Total Energy Consumption:3,293 MWh (2023)

ESG Focus Areas

  • Good Health and Well-being
  • Gender Equality
  • Decent Work and Economic Growth
  • Climate Action

Environmental Achievements

  • Completed our first full carbon footprint assessment of Scope 1, 2, and 3 GHG emissions
  • Opened laboratories and facilities in BREEAM Excellent certified Accelerator building in the Netherlands
  • Applied adaptive re-use of office space at two sites
  • Implemented solution to enable re-use of plastic pipette tips

Social Achievements

  • Increased team member headcount by 544, reaching 2,204 globally
  • Launched Total Rewards & Opportunities and Well-Being programs
  • Achieved 83% engagement score with 88% participation in annual employee survey
  • Conducted pay equity assessment
  • 571 team members volunteered 2,668 hours on Global Volunteer Day
  • Launched Patient Advisory Council
  • Commenced MyNavCare Patient Support™ access program in the U.S.

Governance Achievements

  • Updated our Code of Conduct
  • Established a supplier diversity program in the U.S.
  • Created a Company-wide supplier governance best practices guide
  • Decided to appoint an external Data Protection Officer (DPO)
  • Published a Clinical Trial Transparency Declaration

Climate Goals & Targets

Medium-term Goals:
  • Reduce Scope 3 emissions by 2030 through supplier engagement and responsible sourcing practices by having at least two-thirds of our suppliers, by spend, covered by Paris Agreement aligned climate targets
Short-term Goals:
  • Achieve a 42% reduction in Scope 1 and 2 GHG by 2030 compared to a 2021 baseline year

Environmental Challenges

  • Inability to attract and retain suitably qualified team members as the Company continues to grow
  • Extensive legislative, regulatory and other requirements both during clinical development and commercialization and post-marketing approval
  • Hazardous materials are used in operations and may be used by our partners and suppliers and must comply with environmental laws and regulations
  • Inability to manage the carbon footprint from our business operations or climate-related events may impact our business operations or that of our third-party partners or suppliers
  • Primarily dependent on one contract manufacturing organization and individual sites at the CMO to produce and supply our product candidates
  • Risks associated with global health crises, epidemics, pandemics and other outbreaks
Mitigation Strategies
  • Competitive remuneration packages, including share-based remuneration; positive and energizing working environment with development and training opportunities; strong core values
  • Robust compliance program, including a Code of Conduct; data protection area supported by the Company’s Data Protection Officer; quality assurance department; Internal Audit function; relevant procedures and guidelines to ensure transparency
  • Annual audits of laboratory waste; team members instructed to replace highly toxic chemicals with less toxic versions where feasible; zero lab wastes discharged into drains
  • Assessment of carbon footprint and implementation of the TCFD recommendations; calculated Scope 1 and 2 emissions; completed 2022 Scope 3 footprint; scenario analysis to evaluate risks and opportunities
  • Oversee outsourcing and partnership relationships; assessment of contingency plans; availability of alternative service providers; evaluation of financial solvency; code of conduct for suppliers
  • Business continuity plans in place across our global supply chain network

Supply Chain Management

Supplier Audits: 2,700+ suppliers went through vetting process (2023)

Responsible Procurement
  • Supplier Code of Conduct

Climate-Related Risks & Opportunities

Transition Risks
  • Carbon taxes, pricing and tariffs

Reporting Standards

Frameworks Used: TCFD

Certifications: Nasdaq ESG Transparency Partner

UN Sustainable Development Goals

  • 3
  • 5
  • 8
  • 13

See report section on Sustainable Development Goals

Awards & Recognition

  • Netherlands Academy of Engineering recognition of CEO
  • Endpoints “Top 20 Women in Biopharma R&D” inclusion of Executive VP and CSO
  • The Medicine Maker Power List 2023 recognition of CEO
  • Spar Nord Danish Bank and BDO’s Successful Business 2023 Award
  • Lymphoma Research Foundation’s Corporate Leadership Award 2023
  • Top Employers Institute’s Top Employer 2023 in Denmark, the Netherlands and the U.S.
  • NJBIZ Best Place to Work’s Top 10
  • Forbes Global 2000 List